Kawauchi Kiyotaka, Ogasawara Toshie
Tokyo Women's Medical University, Adachi Medical Center, Department of Medicine, 4-33-1 Kohoku Adachi-ku, Tokyo, Japan.
Leuk Res Rep. 2024 Dec 19;23:100497. doi: 10.1016/j.lrr.2024.100497. eCollection 2025.
Primary effusion lymphoma (PEL)-like lymphoma is a rare variant of PEL that exhibits diverse clinical behaviors, ranging from mild to aggressive disease courses. The clinicopathological features and effective treatments for this type of lymphoma have not been well defined. We found that proteasome inhibitors were effective in inhibiting the growth and survival of OGU1 cells, which were derived from a patient with aggressive PEL-like lymphoma, highlighting the critical role of proteasome activity in the proliferation of PEL-like lymphoma cells. This suggests that proteasome inhibitors, such as bortezomib, could be promising therapeutic options for patients who respond poorly to conventional chemotherapy.
原发性渗出性淋巴瘤（PEL）样淋巴瘤是PEL的一种罕见变体，表现出从轻度到侵袭性病程的多种临床行为。这种类型淋巴瘤的临床病理特征和有效治疗方法尚未明确界定。我们发现蛋白酶体抑制剂可有效抑制OGU1细胞的生长和存活，OGU1细胞源自一名侵袭性PEL样淋巴瘤患者，这突出了蛋白酶体活性在PEL样淋巴瘤细胞增殖中的关键作用。这表明蛋白酶体抑制剂，如硼替佐米，对于对传统化疗反应不佳的患者可能是有前景的治疗选择。
